title: Glycemic control prevents microvascular remodeling and increased tone in type 2 diabetes: link to endothelin-1.
abstract: Medial thickening and vascular hypertrophy of resistance arteries can lead to cardiovascular complications associated with diabetes. While previous studies have established a role of type 1 diabetes in vascular remodeling, we recently extended these observations to type 2 diabetes and reported increased collagen deposition due to alterations in matrix metalloproteinase expression and activity in mesenteric resistance arteries. These studies also showed that remodeling response was mediated by endothelin-1 (ET-1) via activation of ET(A) receptors, whereas blockade of ET(B) receptors exacerbated the remodeling. However, the effectiveness of glycemic control strategies in preventing these vascular changes, including activation of the ET system still remained unclear. Also, very little is known about whether and to what extent reorganization of the extracellular matrix (ECM) affects vascular compliance and vasomotor tone. Accordingly, this study assessed structural remodeling of mesenteric microvessels, vascular compliance, and myogenic tone, as well as the role of matrix metalloproteinases (MMP) in mediating these processes. Spontaneously diabetic, non-obese Goto-Kakizaki (GK) rats, a model for type 2 diabetes, and normoglycemic Wistar rats were used for the studies. A subset of GK rats were administered metformin to achieve euglycemia. Glycemic control normalized the increased media-to-lumen ratios (M/L) and myogenic tone seen in diabetes, as well as normalizing plasma ET-1 levels and mesenteric ET(A) receptor expression. There was increased collagen synthesis in diabetes paralleled by decreased collagenase MMP-13 activity, while glycemic control attenuated the process. These findings and our previous study taken together suggest that hyperglycemia-mediated activation of ET-1 and ET(A) receptors alter vascular structure and mechanics in type 2 diabetes.
authors.affiliation: Medical College of Georgia, Augusta, GA 30912, USA.
authors.forename: Kamakshi
authors.initials: K
authors.lastname: Sachidanandam
authors.forename: Jim R
authors.initials: JR
authors.lastname: Hutchinson
authors.forename: Mostafa M
authors.initials: MM
authors.lastname: Elgebaly
authors.forename: Erin M
authors.initials: EM
authors.lastname: Mezzetti
authors.forename: Anne M
authors.initials: AM
authors.lastname: Dorrance
authors.forename: Kouros
authors.initials: K
authors.lastname: Motamed
authors.forename: Adviye
authors.initials: A
authors.lastname: Ergul
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000187:drug effects* / Q000378:metabolism; D003094:Collagen / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D004195:Disease Models, Animal; D019332:Endothelin-1 / Q000378:metabolism*; D006965:Hyperplasia; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D008297:Male; D053509:Matrix Metalloproteinase 13 / Q000378:metabolism; D008638:Mesenteric Arteries / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D008687:Metformin / Q000494:pharmacology*; D055806:Microvessels / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D051381:Rats; D017208:Rats, Wistar; D044022:Receptor, Endothelin A / Q000378:metabolism; D044023:Receptor, Endothelin B / Q000378:metabolism; D014661:Vasoconstriction / Q000187:drug effects*
chemical_list: D001786:Blood Glucose; D019332:Endothelin-1; D007004:Hypoglycemic Agents; D044022:Receptor, Endothelin A; D044023:Receptor, Endothelin B; D003094:Collagen; D008687:Metformin; D053509:Matrix Metalloproteinase 13; C507083:Mmp13 protein, rat